Russell J Schilder

Russell J Schilder

UNVERIFIED PROFILE

Are you Russell J Schilder?   Register this Author

Register author
Russell J Schilder

Russell J Schilder

Publications by authors named "Russell J Schilder"

Are you Russell J Schilder?   Register this Author

66Publications

1253Reads

9Profile Views

Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.

JAMA Oncol 2019 06;5(6):910-911

Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.0562DOI Listing
June 2019

Brain Metastases in Patients with Gynecologic Cancers: A Single Institution Experience and Review of the Literature.

Open J Obstet Gynecol 2016 Aug 15;6(9):544-552. Epub 2016 Aug 15.

Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4236/ojog.2016.69070DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6758932PMC
August 2016

Hereditary ovarian cancer: not only BRCA 1 and 2 genes.

Biomed Res Int 2015 17;2015:341723. Epub 2015 May 17.

Department of Oncology, Haematology and Respiratory Diseases, University Hospital of Modena, 41124 Modena, Italy.

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/bmri/2015/341723/
Publisher Site
http://dx.doi.org/10.1155/2015/341723DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449870PMC
March 2016

Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer.

J Contemp Brachytherapy 2014 Oct 5;6(3):262-70. Epub 2014 Sep 5.

Department of Radiation Oncology, Kimmel Cancer Center, Thomas Jefferson University Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/jcb.2014.45031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200177PMC
October 2014

Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.

Int J Womens Health 2014 28;6:149-57. Epub 2014 Jan 28.

Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJWH.S40889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913505PMC
June 2014

Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report.

Gynecol Oncol Case Rep 2013 1;6:7-9. Epub 2013 Jul 1.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gynor.2013.06.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862313PMC
December 2013

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.

Mol Cancer Ther 2013 Jul 24;12(7):1367-77. Epub 2013 Apr 24.

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852914PMC
July 2013

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

Gynecol Oncol 2012 Dec 7;127(3):456-61. Epub 2012 Sep 7.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Oklahoma, Oklahoma City, OK 73190, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2012.08.030DOI Listing
December 2012

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Gynecol Oncol 2009 Nov 26;115(2):215-20. Epub 2009 Aug 26.

The Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.07.023DOI Listing
November 2009

A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

Int J Gynecol Cancer 2009 Jul;19(5):929-33

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/IGC.0b013e3181a83467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722934PMC
July 2009

Management of recurrent ovarian carcinoma: current status and future directions.

Semin Oncol 2009 Apr;36(2):112-25

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2008.12.003DOI Listing
April 2009

Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis.

Cancer Genomics Proteomics 2008 May-Aug;5(3-4):137-49

Division of Basic Science, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111-2497, USA.

View Article

Download full-text PDF

Source
October 2008

Platinum resistance: the role of DNA repair pathways.

Clin Cancer Res 2008 Mar;14(5):1291-5

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-2238DOI Listing
March 2008

Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects.

J Natl Compr Canc Netw 2006 Oct;4(9):955-66

From Fox Chase Cancer Center, Philadelphia, Pennsylvania, PA 19103, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2006.0079DOI Listing
October 2006

Imatinib mesylate and its potential implications for gynecologic cancers.

Curr Treat Options Oncol 2005 Mar;6(2):115-20

Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-005-0019-9DOI Listing
March 2005

Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.

Gynecol Oncol 2005 Jan;96(1):103-7

Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2004.09.027DOI Listing
January 2005

Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.

Invest New Drugs 2004 Aug;22(3):343-9

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/B:DRUG.0000026262.77502.31DOI Listing
August 2004

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.

Blood 2004 Jun 11;103(12):4429-31. Epub 2004 Mar 11.

Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, 676 N St Clair, Ste 850, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2003-11-38
Publisher Site
http://dx.doi.org/10.1182/blood-2003-11-3883DOI Listing
June 2004

Focus on epithelial ovarian cancer.

Cancer Cell 2004 Jan;5(1):19-24

Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1535-6108(04)00002-9DOI Listing
January 2004

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Semin Nucl Med 2004 Jan;34(1 Suppl 1):4-9

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semnuclmed.2003.11.002DOI Listing
January 2004

Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.

Cancer Chemother Pharmacol 2002 Sep 16;50(3):243-50. Epub 2002 Jul 16.

Department of Pharacology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-002-0490-yDOI Listing
September 2002